Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 101.73B +21.2% |
| Revenue (ttm) | 25.29B +20.7% |
| Net Income | 5.32B -27.7% |
| EPS | 84.98 -25.8% |
| Shares Out | 61.39M |
| PE Ratio | 19.50 |
| Forward PE | 20.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,942 |
| Average Volume | 148,781 |
| Open | 1,635.50 |
| Previous Close | 1,657.00 |
| Day's Range | 1,620.00 - 1,671.00 |
| 52-Week Range | 1,275.00 - 2,257.00 |
| Beta | 0.70 |
| RSI | 42.00 |
| Earnings Date | May 7, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase i...
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. Published first on…
Genmab announces 5.08% stake by Orbis Investment
Genmab (GMAB) announces that Orbis Investment Management has informed the company that through shares, as of May 8, it controlled the voting rights to 3,166,357 shares in Genmab, which amounts…
Genmab price target lowered to $33 from $34 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares.
Genmab reports Q1 operating profit $180M, consensus $172.7M
Reports Q1 revenue $896M, consensus $901.1M. “We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio – EPKINLY, Rina-S and petosemtamab.
Genmab maintains FY26 guidance
Genmab (GMAB) is maintaining its 2026 financial guidance published February 17, the company stated with its Q1 report.
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA appro...
Genmab price target lowered to $38 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Genmab (GMAB) to $38 from $40 and keeps a Buy rating on the shares. Given Pfizer’s results from the MagnetisMM-5 trial, the…
Genmab upgraded to Outperform from Neutral at BNP Paribas
BNP Paribas upgraded Genmab (GMAB) to Outperform from Neutral with a DKK 2,400 price target
Genmab upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Rajan Sharma upgraded Genmab (GMAB) to Buy from Neutral with a $30.50 price target The firm sees a “catalyst-rich” 2026 for Genmab and a favorable risk/reward for…
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with ...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...
Genmab reports Darzalex Q1 worldwide sales $3.964B
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DA...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab presents safety, tolerability data on Rina-S with bevacizumab
Genmab (GMAB) announced new data demonstrating that rinatabart sesutecan, an investigational folate receptor alpha-targeted, topoisomerase I inhibitor antibody-drug conjugate, evaluated in combination...
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, top...
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and...
Genmab initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Genmab (GMAB) with an Outperform rating and $32 price target The company is facing a “critical” loss of exclusivity in 2029, but should fully replenish…
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 19, 2026, the Company's Board of Directors met to consti...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management...
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announ...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 share...
Correction to Company Announcement No. 13 of March 2, 2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
Genmab initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Genmab (GMAB) with an Overweight rating and $40 price target The firm believes the company’s upcoming Epkinly and petosemtamab readouts are “largely de-risked” based ...